Brent A. Neuschwander-Tetri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Brent A. Neuschwander-Tetri has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
Elizabeth M. Brunt
Department of Pathology and Immunology Washington University Saint Louis USA
4 shared publicationsVanita Talkad
Departments of 1Internal Medicine and
4 shared publications- David E. Kleiner
Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, USA
3 shared publications James Tonascia
Johns Hopkins University, Baltimore, MD, USA
3 shared publicationsLaura H. Tetri
Division of Gastroenterology and Hepatology, Department of Internal Medicine Saint Louis University Saint Louis USA
3 shared publicationsMetin Basaranoglu
Division of Gastroenterology and Hepatology, Department of Internal Medicine Saint Louis University Saint Louis USA
3 shared publications
Latest Publications
- 31 August 2017
- Published by Wolters Kluwer Health in Hepatology
- Vol. 67 (1) , 134-144
Performance characteristics of vibration‐controlled transient elastography for evaluation of nonalcoholic fatty liver disease
Vibration‐controlled transient elastography estimates liver stiffness measurement (LSM) and controlled attenuation parameter (CAP), which are noninvasive assessments of hepatic fibrosis and steatosis, respectively. However, prior vibration‐controlled transient elastography studies reported high failure rates in patients with nonalcoholic fatty liver disease. We examined the performance characteristics of the FibroScan 502 Touch with two probes, medium (M+) and extra large (XL+), in patients with nonalcoholic fatty liver disease in a multicenter setting. A total of 1,696 exams were attempted in 992 patients (body mass index, 33.6 ± 6.5 kg/m2) with histologically confirmed nonalcoholic fatty liver disease. Simultaneous assessment of LSM and CAP was performed using the FibroScan 502 Touch with an automatic probe selection tool. Testing was conducted twice in patients by either a single operator (87%) or two operators (13%). Failure was defined as the inability to obtain a valid examination. An examination was considered unreliable if LSM interquartile range/median was >30%. Significant disagreement between two readings was defined as >95% limits of agreement between two readings. A total of 1,641 examinations yielded valid results with a failure rate of 3.2% (55/1,696). The proportion of unreliable scans for LSM was 3.9%. The proportion of unreliable scans with operator experience in the top quartile (≥59 procedures) was significantly lower than that in the lower three quarters combined (1.6% versus 4.7%,P= 0.02 by Fisher's exact test). The significant disagreement between first and second readings for LSM and CAP when obtained back to back was 18% and 11%, respectively.Conclusion:Vibration‐controlled transient elastography for estimation of LSM and CAP can be successfully deployed in a multicenter setting with low failure (3.2%) and high reliability (>95%) rates and high reproducibility. (Hepatology2018;67:134‐144).
- 31 August 2017
- Published by Wolters Kluwer Health in Hepatology
- Vol. 67 (1) , 134-144
Performance characteristics of vibration‐controlled transient elastography for evaluation of nonalcoholic fatty liver disease
Vibration‐controlled transient elastography estimates liver stiffness measurement (LSM) and controlled attenuation parameter (CAP), which are noninvasive assessments of hepatic fibrosis and steatosis, respectively. However, prior vibration‐controlled transient elastography studies reported high failure rates in patients with nonalcoholic fatty liver disease. We examined the performance characteristics of the FibroScan 502 Touch with two probes, medium (M+) and extra large (XL+), in patients with nonalcoholic fatty liver disease in a multicenter setting. A total of 1,696 exams were attempted in 992 patients (body mass index, 33.6 ± 6.5 kg/m2) with histologically confirmed nonalcoholic fatty liver disease. Simultaneous assessment of LSM and CAP was performed using the FibroScan 502 Touch with an automatic probe selection tool. Testing was conducted twice in patients by either a single operator (87%) or two operators (13%). Failure was defined as the inability to obtain a valid examination. An examination was considered unreliable if LSM interquartile range/median was >30%. Significant disagreement between two readings was defined as >95% limits of agreement between two readings. A total of 1,641 examinations yielded valid results with a failure rate of 3.2% (55/1,696). The proportion of unreliable scans for LSM was 3.9%. The proportion of unreliable scans with operator experience in the top quartile (≥59 procedures) was significantly lower than that in the lower three quarters combined (1.6% versus 4.7%,P= 0.02 by Fisher's exact test). The significant disagreement between first and second readings for LSM and CAP when obtained back to back was 18% and 11%, respectively.Conclusion:Vibration‐controlled transient elastography for estimation of LSM and CAP can be successfully deployed in a multicenter setting with low failure (3.2%) and high reliability (>95%) rates and high reproducibility. (Hepatology2018;67:134‐144).
- Top Cited PapersOpen Access
- 28 February 2017
- Published by Springer Nature in BMC Medicine
- Vol. 15 (1) , 1-6
Non-alcoholic fatty liver disease
Non-alcoholic fatty liver disease has emerged a major challenge because of it prevalence, difficulties in diagnosis, complex pathogenesis, and lack of approved therapies. As the burden of hepatitis C abates over the next decade, non-alcoholic fatty liver disease will become the major form of chronic liver disease in adults and children and could become the leading indication for liver transplantation. This overview briefly summarizes the most recent data on the pathophysiology, diagnosis, and treatment of non-alcoholic fatty liver disease. Ongoing clinical trials are focused on an array of disease mechanisms and reviewed here are how these treatments fit into the current paradigm of substrate overload lipotoxic liver injury. Many of the approaches are directed at downstream events such as inflammation, injury and fibrogenesis. Addressing more proximal processes such as dysfunctional satiety mechanisms and inappropriately parsimonious energy dissipation are potential therapeutic opportunities that if successfully understood and exploited would not only address fatty liver disease but also the other components of the metabolic syndrome such as obesity, diabetes and dyslipidemia.
- 28 February 2017
- Published by Springer Nature in BMC Medicine
- Vol. 15 (1) , 1-6
Top Cited PapersOpen AccessNon-alcoholic fatty liver disease
Non-alcoholic fatty liver disease has emerged a major challenge because of it prevalence, difficulties in diagnosis, complex pathogenesis, and lack of approved therapies. As the burden of hepatitis C abates over the next decade, non-alcoholic fatty liver disease will become the major form of chronic liver disease in adults and children and could become the leading indication for liver transplantation. This overview briefly summarizes the most recent data on the pathophysiology, diagnosis, and treatment of non-alcoholic fatty liver disease. Ongoing clinical trials are focused on an array of disease mechanisms and reviewed here are how these treatments fit into the current paradigm of substrate overload lipotoxic liver injury. Many of the approaches are directed at downstream events such as inflammation, injury and fibrogenesis. Addressing more proximal processes such as dysfunctional satiety mechanisms and inappropriately parsimonious energy dissipation are potential therapeutic opportunities that if successfully understood and exploited would not only address fatty liver disease but also the other components of the metabolic syndrome such as obesity, diabetes and dyslipidemia.
- 12 April 2016
- Published by Springer Nature in Current Hepatology Reports
- Vol. 15 (2) , 125-133
Future Treatments of NASH
- 12 April 2016
- Published by Springer Nature in Current Hepatology Reports
- Vol. 15 (2) , 125-133
Future Treatments of NASH
- 1 July 2015
- Published by Elsevier in The Lancet
- Vol. 386 (9988) , 28-29
Trials of obeticholic acid for non-alcoholic steatohepatitis – Authors' reply
- 1 July 2015
- Published by Elsevier in The Lancet
- Vol. 386 (9988) , 28-29
Trials of obeticholic acid for non-alcoholic steatohepatitis – Authors' reply
- 1 July 2015
- Published by Elsevier in The American Journal of Clinical Nutrition
- Vol. 102 (1) , 5-6
Retinoid X receptor: the forgotten partner in regulating lipid metabolism?
- 1 July 2015
- Published by Elsevier in The American Journal of Clinical Nutrition
- Vol. 102 (1) , 5-6
Retinoid X receptor: the forgotten partner in regulating lipid metabolism?
- 1 April 2015
- Published by Elsevier in Gastroenterology
- Vol. 148 (4) , 704-706
Targeting the FXR Nuclear Receptor to Treat Liver Disease
- 1 April 2015
- Published by Elsevier in Gastroenterology
- Vol. 148 (4) , 704-706
Targeting the FXR Nuclear Receptor to Treat Liver Disease
- Top Cited Papers
- 1 March 2015
- Published by Elsevier in The Lancet
- Vol. 385 (9972) , 956-965
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
- 1 March 2015
- Published by Elsevier in The Lancet
- Vol. 385 (9972) , 956-965
Top Cited PapersFarnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
- 1 July 2013
- Published by Wolters Kluwer Health in Current Opinion in Clinical Nutrition and Metabolic Care
- Vol. 16 (4) , 446-452
Carbohydrate intake and nonalcoholic fatty liver disease
Carbohydrate consumption has been implicated in the metabolic syndrome and nonalcoholic fatty liver disease (NAFLD). Reviewed here is basis for this relationship and the recent additional evidence that excessive dietary carbohydrate consumption, especially excessive fructose or sucrose consumption, is playing a role in the epidemic of NAFLD. A recent cross-sectional epidemiological study has linked fructose consumption to the severity of fibrosis in patients with NAFLD. Clinical trials have shown that consumption of fructose-containing beverages, either has fructose or sucrose, contribute to the development of NAFLD compared to isocaloric alternatives, and that genetic polymorphisms that increase the entry of glucose into lipogenic pathways are associated with fatty liver disease. New animal studies provide additional evidence on the role of carbohydrate-induced de-novo lipogenesis and the gut microbiome in fructose-induced NAFLD. Data also suggest that fructose-induced uric acid production in the liver also plays a role in NAFLD independent of the role of fructose as a substrate for lipogenesis. Epidemiological studies, clinical trials, and animal studies continue to point to excess dietary carbohydrate, and especially fructose, in contributing to the risk factors for NAFLD.
- 1 July 2013
- Published by Wolters Kluwer Health in Current Opinion in Clinical Nutrition and Metabolic Care
- Vol. 16 (4) , 446-452
Carbohydrate intake and nonalcoholic fatty liver disease
Carbohydrate consumption has been implicated in the metabolic syndrome and nonalcoholic fatty liver disease (NAFLD). Reviewed here is basis for this relationship and the recent additional evidence that excessive dietary carbohydrate consumption, especially excessive fructose or sucrose consumption, is playing a role in the epidemic of NAFLD. A recent cross-sectional epidemiological study has linked fructose consumption to the severity of fibrosis in patients with NAFLD. Clinical trials have shown that consumption of fructose-containing beverages, either has fructose or sucrose, contribute to the development of NAFLD compared to isocaloric alternatives, and that genetic polymorphisms that increase the entry of glucose into lipogenic pathways are associated with fatty liver disease. New animal studies provide additional evidence on the role of carbohydrate-induced de-novo lipogenesis and the gut microbiome in fructose-induced NAFLD. Data also suggest that fructose-induced uric acid production in the liver also plays a role in NAFLD independent of the role of fructose as a substrate for lipogenesis. Epidemiological studies, clinical trials, and animal studies continue to point to excess dietary carbohydrate, and especially fructose, in contributing to the risk factors for NAFLD.
- 1 May 2013
- Published by Elsevier in Gastroenterology
- Vol. 144 (5)
804 Hepatic Zonation in a Nonalcoholic Steatohepatitis Mouse Model
- 1 May 2013
- Published by Elsevier in Gastroenterology
- Vol. 144 (5)
804 Hepatic Zonation in a Nonalcoholic Steatohepatitis Mouse Model
Dietary trans‐Fatty Acid Induced NASH is Normalized Following Loss of trans‐Fatty Acids from Hepatic Lipid Pools
Previous experiments in mice showed that dietary trans‐fats could play a role in non‐alcoholic steatohepatitis (NASH) yet little is known about the accumulation trans‐fats in hepatic lipid pools in relationship to liver injury. NASH is also associated with obesity yet improves with only modest weight loss. To distinguish the role of obesity versus sustained consumption of a trans‐fat containing diet in causing NASH, mice with obesity and NASH induced by consuming a high trans‐fat diet for 16 weeks were subsequently fed standard chow or maintained on trans‐fat chow for another 8 weeks. The accumulation, partitioning and loss of trans‐fats in the major hepatic lipid pools during and after trans‐fat consumption were determined. Obese mice switched to standard chow remained obese but steatohepatitis improved. trans‐fats were differentially incorporated into the major hepatic lipid pools and the loss of trans‐fats after crossover to control chow was greatest in the cholesteryl ester pool. In summary, dietary changes can improve the biochemical and histopathological changes of NASH despite persistent obesity in mice. Analysis of hepatic lipids confirmed that dietary trans‐fats accumulate in the major lipid pools and are released differentially with diet normalization. The substantial loss of trans‐fats from the cholesteryl ester pool in parallel with improvement in NASH suggests that this pool of trans‐fats could play a role in the pathogenesis of NASH.
Dietary trans‐Fatty Acid Induced NASH is Normalized Following Loss of trans‐Fatty Acids from Hepatic Lipid Pools
Previous experiments in mice showed that dietary trans‐fats could play a role in non‐alcoholic steatohepatitis (NASH) yet little is known about the accumulation trans‐fats in hepatic lipid pools in relationship to liver injury. NASH is also associated with obesity yet improves with only modest weight loss. To distinguish the role of obesity versus sustained consumption of a trans‐fat containing diet in causing NASH, mice with obesity and NASH induced by consuming a high trans‐fat diet for 16 weeks were subsequently fed standard chow or maintained on trans‐fat chow for another 8 weeks. The accumulation, partitioning and loss of trans‐fats in the major hepatic lipid pools during and after trans‐fat consumption were determined. Obese mice switched to standard chow remained obese but steatohepatitis improved. trans‐fats were differentially incorporated into the major hepatic lipid pools and the loss of trans‐fats after crossover to control chow was greatest in the cholesteryl ester pool. In summary, dietary changes can improve the biochemical and histopathological changes of NASH despite persistent obesity in mice. Analysis of hepatic lipids confirmed that dietary trans‐fats accumulate in the major lipid pools and are released differentially with diet normalization. The substantial loss of trans‐fats from the cholesteryl ester pool in parallel with improvement in NASH suggests that this pool of trans‐fats could play a role in the pathogenesis of NASH.